Who are Dextromethorphan hydrobromide with guaifenesin's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dextromethorphan-hydrobromide-with-guaifenesin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Dextromethorphan hydrobromide with guaifenesin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dextromethorphan hydrobromide with guaifenesin (Dextromethorphan hydrobromide with guaifenesin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antitussive/expectorant combination. Area: Respiratory/Cough.

marketed Antitussive/expectorant combination Sigma-1 receptor, NMDA receptor (dextromethorphan); non-specific expectorant mechanism (guaifenesin) Respiratory/Cough Small molecule Live · refreshed every 30 min

Target snapshot

Dextromethorphan hydrobromide with guaifenesin (Dextromethorphan hydrobromide with guaifenesin) — Washington University School of Medicine. Dextromethorphan suppresses cough by acting as a non-opioid antitussive agent in the central nervous system, while guaifenesin thins mucus to facilitate clearance.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Dextromethorphan hydrobromide with guaifenesin TARGET	Dextromethorphan hydrobromide with guaifenesin	Washington University School of Medicine	marketed	Antitussive/expectorant combination	Sigma-1 receptor, NMDA receptor (dextromethorphan); non-specific expectorant mechanism (guaifenesin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antitussive/expectorant combination class)

Washington University School of Medicine · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Dextromethorphan hydrobromide with guaifenesin — Competitive Intelligence Brief. https://druglandscape.com/ci/dextromethorphan-hydrobromide-with-guaifenesin. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab